Search Results - Resource Center

PUBLICATIONS

Publication - Abstract

Oct 10, 2021
Journal of Controlled Release

Polymeric and Lipid Nanoparticles for Delivery of Self-Amplifying RNA Vaccines

A.K. Blakney, P.F. McKay, K. Hu, K. Samnuan, N. Jain, A. Brown, A. Thomas, P. Rogers, K. Polra, H. Sallah, J. Yeow, Y. Zhu, M.M. Stevens, A. Geall, and R.J. Shattock

To investigate the role of different biomaterials in self-amplifying RNA vaccines, a scientific article authored by Anna Blakney et al. 2021 at the University of British Columbia in collaboration with scientists from Precision NanoSystems Inc., and Imperial College London compare...
Read More
Publication - Abstract

Jan 28, 2021
Vaccines

An Update on Self-Amplifying mRNA Vaccine Development

A.K. Blakney, S. Ip. and A.J. Geall

Vaccines Nucleic Acid Lipid Nanoparticles mRNA

This review will explore the four major pillars required for design and development of an saRNA vaccine: Antigen design, vector design, non-viral delivery systems, and manufacturing (both saRNA and lipid nanoparticles (LNP)). We report on the major innovations, preclinical a...
Read More
Publication - Abstract

Dec 21, 2020
Molecular Therapy

Innate Inhibiting Proteins Enhance Expression and Immunogenicity of Self-Amplifying RNA

A.K. Blakney, P.F. McKay, C.R. Bouton, K. Hu, K. Samnuan and R.J. Shattock

mRNA Vaccines Polymeric Nanoparticles

Abstract
Self-amplifying RNA (saRNA) is a cutting-edge platform for both nucleic acid vaccines and therapeutics. saRNA is self-adjuvanting, as it activates types I and III interferon (IFN), which enhances the immunogenicity of RNA vaccines but can also lead to inhibition...
Read More
Publication - Abstract

Jul 01, 2020
Journal of Controlled Release

Delivery of Self-amplifying mRNA Vaccines by Cationic Lipid Nanoparticles: The Impact of Cationic Lipid Selection

G. Lou, G. Anderluzzi, S.T. Schmidt, S. Woods, S. Gallorini, M. Brazzoli, F. Giusti, I. Ferlenghi, R. Johnson, C.W. Roberts, D.T. O'Hagan, B.C. Baudner and Y. Perrie

Other Applications Nucleic Acid Lipid Nanoparticles mRNA

Self-amplifying RNA (SAM) represents a versatile tool that can be used to develop potent vaccines, potentially able to elicit strong antigen-specific humoral and cellular-mediated immune responses to virtually any infectious disease. To protect the SAM from degradation and achiev...
Read More
Publication - Abstract

May 08, 2020
Vaccines

Investigating the Impact of Delivery System Design on the Efficacy of Self-Amplifying RNA Vaccines

G. Anderluzzi, G. Lou, S. Gallorini, M. Brazzoli, R. Johnson, D.T. O'Hagan, B.C. Baudner and Y. Perrie

mRNA Polymeric Nanoparticles Nucleic Acid Lipid Nanoparticles

messenger RNA (mRNA)-based vaccines combine the positive attributes of both live-attenuated and subunit vaccines. In order for these to be applied for clinical use, they require to be formulated with delivery systems. However, there are limited in vivo studies which compare ...
Read More
Publication - Abstract

Feb 25, 2021
Molecular Cancer

mRNA Vaccine for Cancer Immunotherapy

L. Miao, Y. Zhang and L. Huang

mRNA Nucleic Acid Lipid Nanoparticles Other Formulations

mRNA vaccines have become a promising platform for cancer immunotherapy. During vaccination, naked or vehicle loaded mRNA vaccines efficiently express tumor antigens in antigen-presenting cells (APCs), facilitate APC activation and innate/adaptive immune stimulation. mRNA cancer ...
Read More

POSTERS

Poster

Nov 09, 2021

Accelerated Development of Self-amplifying mRNA (saRNA) Vaccines using Microfluidics

Download
Poster

Sep 20, 2021

Scale Up and Manufacturing of Self-amplifying RNA-LNPs for a COVID-19 Vaccine Using the NanoAssemblr® GMP System

Download

VIDEOS & WEBINARS

Webinar

Mar 31, 2020

Non Viral Delivery of self amplifying mRNA Vaccines

Dr. Andy Geall will walk us through the history and commercial mRNA vaccine landscape, the background to the SAM (self-amplifying mRNA) vaccine platform and non-viral delivery. He will also discuss preclinical data of the application in pandemic influenza, and the translation fro...

ARTICLES

Article

Jul 28, 2022

How Lipid Nanoparticle (LNP) Technology Meets the Delivery Need Of Breakthrough saRNA Vaccine

Vaccines Nucleic Acid Lipid Nanoparticles mRNA

RNA vaccines are hugely versatile. They can potentially inoculate against any pathogen for which a protein target is known, for example, influenza, chlamydia, HIV-1 (human immunodeficiency virus 1), Ebola and RSV (respiratory syncytial virus). Self-amplifying RNA (saRNA) is a typ...
Read More

Resource Center Search

PUBLICATIONS

Polymeric and Lipid Nanoparticles for Delivery of Self-Amplifying RNA Vaccines

An Update on Self-Amplifying mRNA Vaccine Development

Innate Inhibiting Proteins Enhance Expression and Immunogenicity of Self-Amplifying RNA

Abstract

Delivery of Self-amplifying mRNA Vaccines by Cationic Lipid Nanoparticles: The Impact of Cationic Lipid Selection

Investigating the Impact of Delivery System Design on the Efficacy of Self-Amplifying RNA Vaccines

mRNA Vaccine for Cancer Immunotherapy

POSTERS

Accelerated Development of Self-amplifying mRNA (saRNA) Vaccines using Microfluidics

Scale Up and Manufacturing of Self-amplifying RNA-LNPs for a COVID-19 Vaccine Using the NanoAssemblr® GMP System

VIDEOS & WEBINARS

Non Viral Delivery of self amplifying mRNA Vaccines

ARTICLES

How Lipid Nanoparticle (LNP) Technology Meets the Delivery Need Of Breakthrough saRNA Vaccine

Advanced Search

Browse by Category